Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Why Intellia Therapeutics Stock Is Sinking Today
03:31pm, Thursday, 04'th Aug 2022 The Motley Fool
Investors are reacting negatively to the company's Q2 update.
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
03:03pm, Thursday, 04'th Aug 2022
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call Transcript
12:57pm, Thursday, 04'th Aug 2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2022 Results Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate C
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
12:39pm, Thursday, 04'th Aug 2022
A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Edit
Why Intellia Therapeutics Stock Is Sinking Today
11:31am, Thursday, 04'th Aug 2022
Investors are reacting negatively to the company's Q2 update.
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
11:30am, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies le
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
05:08pm, Wednesday, 03'rd Aug 2022
Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted t
Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely
05:31am, Saturday, 30'th Jul 2022 Seeking Alpha
Intellia’s recent data from its Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate.
Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely
01:31am, Saturday, 30'th Jul 2022
Recent data from Intellia's Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate. Multiple catalysts from new clinical data releases
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
11:30am, Wednesday, 27'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
07:30am, Wednesday, 27'th Jul 2022
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics l
Down 35% This Year, Is This Small-Cap Stock a Buy?
02:30pm, Thursday, 21'st Jul 2022 The Motley Fool
This biotech could be a steal at its current levels, but it could also be a trap.
Is It Time to Buy the Dip With Biotech Stocks?
02:23pm, Thursday, 21'st Jul 2022 The Motley Fool
Right now, it's even riskier to buy biotechs than normal.
Is It Time to Buy the Dip With Biotech Stocks?
10:23am, Thursday, 21'st Jul 2022
Right now, it's even riskier to buy biotechs than normal.
